The results of the in vivo experiment confirmed that CSP therapy ameliorates liver inflammation by inhibiting both the mRNA and protein levels of inflammatory factors, including TNFα, IL-1β, IL-6, and iNOS in the livers of mice with NAFLD. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.